Lundbeck begins phase II trial of antibody for migraine prevention
Antibody treatment Lu AG09222 will be tested in a phase II trial including around 230 patients, the company reports. The candidate uses a different mechanism than the relatively new class of CGRP receptors, which have been gaining ground on the migraine market.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
A few days after receiving pivotal European approval for its migraine drug Vyepti, Lundbeck is moving ahead with another candidate for the treatment of migraines.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
